PE-Backed Pharma Services and Specialty Pharma Operators
The PE roll-up activity in pharma services is concentrated in three operating profiles: pharmacovigilance services aggregators, regulatory affairs services rollups, and clinical data management aggregators. Each of these profiles runs on regulated, audit-bound workflows where the AI-native operating model produces the multiple-arbitrage story buyers underwrite at exit. We build the AI-native org chart and the COPO entity together, calibrated to FDA-ready audit posture, so the institutional residue (PV signals, regulatory submission patterns, study data) compounds inside the operator's entity, not the vendor's.
Ready Infrastructure
Aligned Systems
Pharma Clients
India Offices
What Pharma Teams Build in India
We help pharma and biotech companies build India teams across the drug development lifecycle.
Pharmacovigilance
Adverse event processing, signal detection, periodic safety reports (PSUR/PBRER), and risk management planning. FDA and EMA compliance standards built into every workflow.
Clinical Data Management
Database design, data entry, query management, medical coding (MedDRA, WHO-DD), and database lock activities for clinical trials. Your trial data, your systems, your governance.
Regulatory Affairs
Submission preparation (eCTD), labeling, post-market surveillance documentation, and regulatory intelligence across FDA, EMA, PMDA, and other agencies.
Medical Writing
Clinical study reports, investigator brochures, regulatory submission documents, and scientific publications. Writers with therapeutic area expertise, not generalists.
Biostatistics
Statistical analysis plans, interim analyses, integrated summaries of safety and efficacy, and data visualization for clinical trial programs.
Quality Assurance
GxP compliance, audit support, CAPA management, deviation investigations, and quality systems management for pharmaceutical operations.
Humans Approve Every Regulatory Decision. Virtual Employees Compress The Work Underneath.
Every function we staff runs with Virtual Employees alongside certified professionals.
Pharmacovigilance
Virtual Employees triage adverse event intake, pre-code MedDRA terms, and flag signals for human review. Certified PV officers approve every case.
Clinical Data Management
Virtual Employees run first-pass query generation, discrepancy detection, and coding QC. CDMs review and release.
Regulatory Affairs
Virtual Employees assemble eCTD modules, cross-check labeling against baseline, and flag regulatory intelligence. RA specialists sign every submission.
Medical Writing
Virtual Employees draft first-pass sections, cross-reference protocols, and tighten compliance language. Medical writers own the final voice.
Every Virtual Employee has persistent memory on your compound and therapeutic area. Every action is auditable.
Every output is traceable. Nothing trains a vendor's model on your data.
Why Pharma Companies Are Moving from CROs to Owned Centers
Contract research organizations served pharma well for decades. But the economics and the risks have changed. Here is what is different now.
Data Ownership
Your clinical trial data, your pharmacovigilance signals, your regulatory submissions. In a CRO model, that data sits in the CRO's systems. In an owned center, it sits in yours. When AI transforms drug safety signal detection (and it already is), the company that owns the data owns the advantage.
Regulatory Audit Control
When the FDA audits your pharmacovigilance operation, they audit YOU. In a CRO model, your audit readiness depends on the CRO's documentation practices. In an owned center, you control the SOPs, the training records, the deviation investigations, and the audit trail.
Institutional Knowledge
A pharmacovigilance team that has worked on your compound for three years knows every adverse event pattern, every coding nuance, every regulatory quirk for your therapeutic area. That knowledge does not transfer when you switch CROs. In an owned center, it compounds.
Cost Structure
CRO markups on Indian pharmacovigilance talent run 50-80% above direct cost. Biostatistics margins are even higher. An owned center eliminates the markup and gives you direct access to India's deep pharma talent pool.
Capacity Control
CRO capacity is shared. When multiple sponsors ramp simultaneously, your timelines slip. An owned center gives you dedicated capacity that scales on your schedule, not the CRO's.
Built for FDA-Regulated Operations
Every pharma GCC we build starts with the regulatory framework required by your program and your auditors.
Why India for Pharma Operations
India has the largest number of FDA-approved manufacturing facilities outside the United States. The country produces over 200,000 pharmacy graduates and 50,000 life sciences PhDs annually.
Hyderabad, Pune, and Mumbai are established pharma hubs with deep talent pools in pharmacovigilance, clinical data management, regulatory affairs, and biostatistics. Reliable Group recruits across all six India cities, matching your therapeutic area requirements to the talent markets where that expertise concentrates.
The talent exists. The question is whether it works for a CRO or for you.
A US Pharma Services Company Built a 30-Person Pharmacovigilance Team in India
A US-based pharmaceutical services company needed to scale pharmacovigilance and clinical data management capacity to support a growing sponsor base. CRO subcontracting was eating into margins and creating quality inconsistency. They launched an India center under the COPO model with Reliable Group managing infrastructure, compliance setup, and talent acquisition.
Within four months, 30 pharmacovigilance and CDM professionals were onboarded and processing adverse events against FDA and EMA timelines. GxP-aligned SOPs were in place from week one.
The India team now handles case processing, MedDRA coding, and signal detection for multiple sponsor programs. Quality metrics match the company's US operations, and the direct cost savings funded expansion into regulatory affairs.
Throughput And Compliance Math For Pharmacovigilance And Regulatory
Heads of pharmacovigilance and regulatory affairs leadership are running operations where every case has a regulatory clock, every submission has a regulator audit posture, and every compound has a CRO contract that sunsets the institutional knowledge when it ends. AI-native operations compress the routine triage, coding, and document assembly work without ceding any regulatory decision.
An FDA-ready offshore team inside a compliant entity delivers the cost structure and the data ownership. Both levers together produce a regulated operation that scales with caseload and compounds inside your entity.
Virtual Employees + AI-Native Org Chart
Virtual Employees handle the high-volume, pattern-based work inside pharmacovigilance and regulatory operations. PV case intake, MedDRA pre-coding, and signal flagging for human review. First-pass query generation, discrepancy detection, and coding QC inside clinical data management. eCTD module assembly, labeling cross-check against baseline, and regulatory intelligence flagging inside regulatory affairs.
First-pass section drafting, protocol cross-referencing, and compliance-language tightening inside medical writing. Certified PV officers approve every case. CDMs review and release every dataset.
RA specialists sign every submission. Medical writers own the final voice. Every Virtual Employee has persistent memory on your compound and therapeutic area.
Offshore Team Inside Your Entity
A hired team inside a 21 CFR Part 11-compliant entity you own delivers the cost structure and the data residency. The team operates the Virtual Employees and owns every regulatory decision.
Audit trails sit inside your entity. Persistent memory on your compound and therapeutic area accumulates inside your operation, not a CRO's contract.
Combined Math (Directional)
Directional ranges when both levers are engaged inside a pharmacovigilance or regulatory operation at scale: 35 to 55 percent reduction in case-processing time on PV intake and MedDRA coding, 25 to 40 percent improvement in regulatory-submission throughput, and 30 to 45 percent reduction in fully-loaded operating cost across the function under review. The compounding asset is the persistent memory on your compound, your therapeutic area, and your adverse event profile.
CROs take that knowledge with them when the contract ends. You do not lose it.
How the Blueprint scopes this for your operation: org chart redesign for the regulated function under review, Virtual Employee roster with cost-per-case budgets, offshore team plan inside your compliant entity, 12-month implementation plan. See the AI-Native Org Chart for the operational picture.
Three Failure Modes. Three Answers.
Token costs
MedDRA auto-coding against a large safety database can burn compute. Every Virtual Employee has a cost-per-case budget that sits in the Blueprint.
Governance
An FDA auditor walks in and asks who approved this coding decision. The answer is a named certified PV officer, with timestamp, rationale, and audit trail. Every time.
Persistent memory
The Virtual Employee that coded the last 2,000 cases for your compound knows the term patterns for your adverse event profile. That memory lives inside your entity. CROs take it with them when the contract ends.
Easy to say. Hard to do. That is the work.
Both levers for pharma. Start with the Blueprint.
Three to five weeks. Paid engagement. AI-native org chart for the regulated function under review, Virtual Employee roster with cost-per-case budgets, offshore team plan inside your 21 CFR Part 11-compliant entity, joint unit economics.